DUBLIN - ( BUSINESS WIRE ) - Afimmune, a clinical stage company focused on the development of bioactive lipids for the treatment of inflammatory and cardiometabolic diseases, today presented the main results obtained with Epeleuton in a study using a well-established hamster model for SARS-CoV-2 infection. Epeleuton has already demonstrated positive anti-inflammatory and metabolic effects in phase II clinical trials carried out on patients and conducted by the Company.